State Street’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

State Street’s Portfolio SIOX Stock Details SIOX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-173,621	Closed	-$75.5K	–	4859
2022 Q4	$75.5K	Hold	173,621	–	–	﹤0.01%	4450
2022 Q3	$49K	Hold	173,621	–	–	﹤0.01%	4664
2022 Q2	$63K	Buy	173,621 +6,500	+4%	+$2.69K	﹤0.01%	4677
2022 Q1	$112K	Buy	167,121 +9,921	+6%	+$8.42K	﹤0.01%	4613
2021 Q4	$203K	Buy	157,200 +47,200	+43%	+$83.8K	﹤0.01%	4346
2021 Q3	$239K	Buy	110,000 +30,900	+39%	+$67.2K	﹤0.01%	4293
2021 Q2	$216K	Buy	+79,100	New	+$197K	﹤0.01%	4192
2018 Q4	–	Sell	-10,677	Closed	-$207K	–	3797
2018 Q3	$207K	Hold	10,677	–	–	﹤0.01%	3598
2018 Q2	$193K	Sell	10,677 -59,061	-85%	-$871K	﹤0.01%	3572
2018 Q1	$744K	Sell	69,738 -1,517	-2%	-$24.4K	﹤0.01%	3382
2017 Q4	$3M	Buy	71,255 +807	+1%	+$36.2K	﹤0.01%	3024
2017 Q3	$3.88M	Buy	70,448 +2,083	+3%	+$351K	﹤0.01%	2914
2017 Q2	$12.7M	Buy	68,365 +23,618	+53%	+$4.14M	﹤0.01%	2273
2017 Q1	$5.35M	Buy	44,747 +572	+1%	+$60K	﹤0.01%	2661
2016 Q4	$4.39M	Buy	44,175 +4,020	+10%	+$423K	﹤0.01%	2762
2016 Q3	$4.5M	Buy	40,155 +1,879	+5%	+$226K	﹤0.01%	2615
2016 Q2	$3.93M	Buy	38,276 +12,030	+46%	+$1.2M	﹤0.01%	2744
2016 Q1	$2.41M	Buy	26,246 +3,041	+13%	+$324K	﹤0.01%	2930
2015 Q4	$3.35M	Buy	23,205 +4,709	+25%	+$613K	﹤0.01%	2759
2015 Q3	$1.91M	Buy	+18,496	New	+$2.17M	﹤0.01%	3016

Other funds holding SIOX

JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return

CIA

Cladis Investment Advisory Billings, Montana $182M AUM 33.3% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

BBA

Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return

State Street's SIOX Position: Q1 2023 in Review

State Street sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q1 2023, closing a stake of 173,621 shares — an estimated $75.5K sold.

State Street first reported a position in SIOX in Q3 2015 and held it in 20 quarters. The position peaked at $12.7M in Q2 2017. 4 funds tracked by Wall St. Rank hold SIOX as of Q1 2023.

State Street reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
State Street sold 173,621 Sio Gene Therapies Inc. Common Stock shares in Q1 2023, an estimated $75.5K.
State Street first reported a position in Sio Gene Therapies Inc. Common Stock in Q3 2015 and held it in 20 quarters.
State Street's Sio Gene Therapies Inc. Common Stock position peaked at $12.7M in Q2 2017.
4 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q1 2023.

Based on State Street's 13F filing for Q1 2023, filed 15 May 2023.